07:00 , Sep 28, 2015 |  BC Week In Review  |  Company News

Hemispherx, Emerge Health deal

Hemispherx granted Emerge exclusive rights to develop and commercialize Alferon N Injection in Australia and New Zealand. The companies will collaborate on regulatory approval of the injectable formulation of natural interferon (IFN) alpha in those...
07:00 , Sep 25, 2014 |  BC Innovations  |  Cover Story

Interrupting Ebola

The 2014 Ebola outbreak is the largest in the disease's history and the first in West Africa, where it has reached multiple countries. Although an approved therapy looks far away, five of seven patients given...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Company News

Hemispherx, Swiss Federal Department of Defense, Civil Protection and Sports (DDPS) infectious news

Hemispherx expanded a research deal with the Swiss agency to test Hemispherx's Alferon N Injection and Ampligen rintatolimod against the Ebola virus. DDPS's Swiss Institute for Nuclear, Biological, Chemical Protection will conduct the studies under...
07:00 , May 26, 2014 |  BC Week In Review  |  Company News

Hemispherx, Swiss Federal Department of Defense, Civil Protection and Sports (DDPS) deal

Hemispherx entered a research deal with the Swiss agency to test Hemispherx's Alferon N Injection against wild-type and Tamiflu oseltamivir-resistant H7N9 influenza virus. DDPS's Swiss Institute for Nuclear, Biological, Chemical Protection will conduct the studies...
07:00 , Sep 30, 2013 |  BC Week In Review  |  Clinical News

Hemispherx preclinical data

In vitro, Alferon N Injection and Tamiflu oseltamivir each significantly inhibited wild-type H7N9 influenza virus and led to similar reductions in wild-type H7N9 influenza titer after 48 hours of treatment exposure. Hemispherx also said Alferon...
07:00 , Mar 11, 2013 |  BC Week In Review  |  Clinical News

Naturaferon interferon alfa-n3 regulatory update

Hemispherx said Argentina's National Administration of Drugs, Foods and Medical Technology (ANMAT) approved an expanded label for Naturaferon interferon alfa-n3 to include treatment of any patient who fails or becomes intolerant to recombinant interferon. Partner...
07:00 , Oct 8, 2012 |  BC Week In Review  |  Clinical News

Naturaferon interferon alfa-n3 regulatory update

Hemispherx submitted an amended NDA to Argentina's National Administration of Drugs, Foods and Medical Technology (ANMAT) to expand the label for Naturaferon interferon alfa-n3 to include the treatment of patients with HCV infection who become...
08:00 , Jan 30, 2012 |  BC Week In Review  |  Clinical News

Naturaferon interferon alfa-n3 regulatory update

Hemispherx Biopharma said Argentina approved a regulatory application from marketing partner GP Pharm for Naturaferon interferon alfa-n3 to treat genital warts. GP Pharm, part of Lipotec S.A. (Gava, Spain), has an exclusive license from Hemispherx...
07:00 , Sep 12, 2011 |  BC Week In Review  |  Company News

Armada Health Care LLC, Hemispherx sales and marketing update

Armada will market Hemispherx's Alferon N interferon alfa-n3 in the U.S. The injectable formulation of natural interferon (IFN) alpha is approved to treat genital warts. The deal ends Aug. 14, 2013. Either party may terminate...
07:00 , Aug 22, 2011 |  BC Week In Review  |  Clinical News

Alferon N interferon alfa-n3 regulatory update

Hemispherx Biopharma said GP Pharm submitted a regulatory application in Argentina for Hemispherx's Alferon N interferon alfa-n3 to treat genital warts. Late last year, GP Pharm exercised an option for an exclusive license to market...